Prostaglandin E1 therapy. Is it associated with a higher incidence of wound infection in the cyanotic neonate?

@article{Fleming1984ProstaglandinET,
  title={Prostaglandin E1 therapy. Is it associated with a higher incidence of wound infection in the cyanotic neonate?},
  author={William Harv Fleming and L B Sarafian and Roger H. Kobayashi},
  journal={Chest},
  year={1984},
  volume={85 2},
  pages={241-3}
}
Prostaglandin (PGE1) may be used to maintain ductal patency in the infant with cyanotic congenital heart disease, but the risk of infection may be increased. Between October, 1976 and December, 1982, 38 neonates with complex cyanotic congenital heart disease required operations creating systemic-to-pulmonary artery shunts. Of 13 patients who did not receive PGE1 therapy, none developed a wound infection. Of 25 patients who did receive PGE1 therapy, four (16 percent) developed a significant… CONTINUE READING